Table 2B.
Clinical characteristics of patients with high vs. low levels of sPD-L1.
| Low sPD-L1 (n = 20) | High sPD-L1 (n = 21) | |
|---|---|---|
| Age years (Median, Range) | 66.05 [41–81] | 67.10 [38–77] |
| CRP mg/dL (Median, Range) | 0.9 [0.1–14.6] | 1.6 [0.1–32.8] |
| Leukocytes G/L (Median, Range) | 7.2 [4.5–18.0] | 7.4 [4.3–18.0] |
| CA-19–9 U/mL (Median, Range) | 353 [2.6–16 257] | 1466 [2.6–422 000] |
| CEA ng/mL (Median, Range) | 4.0 [0.7–59.8] | 9.0 [0.2–432] |
| Stage | ||
| Locally advanced pancreatic cancer | 3 | 3 |
| Metastatic pancreatic cancer | 17 | 18 |
| Performance status | ||
| ECOG 0 | 10 | 10 |
| ECOG 1 | 9 | 9 |
| ECOG 2 | 0 | 1 |
| ECOG 3 | 1 | 0 |
| ECOG missing | 0 | 1 |
| Median overall survival (months) | 9.53 [95% CI: 5.06–13.99] | 11.92 [95% CI: 6.41–17.44] |
Abbreviations: CA 19–9: carbohydrate antigen 19–9; CEA: carcinoembryonic antigen; CI, confidence interval; CRP: C-reactive protein; ECOG: Eastern Cooperative Oncology Group performance status; sPD-1, soluble programmed death protein 1; sPD-L1, soluble programmed death-ligand 1.